New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
UPDATE: Owens-Illinois surges on deal; DuPont falls after defeating Trian
FDA panel backs Vertex cystic-fibrosis drug Orkambi
Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study on the Benefits of the Ivacaftor/Lumacaftor Combination Drug (Orkambi) To Treat Cystic Fibrosis
Across the Country, Great Strides Are Underway to Find a Cure for Cystic Fibrosis
Vertex's Cystic-Fibrosis Drug Faces Big Test
Options on this firm's blockbuster cost a little but pay off big.
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
We dive into the process for adding companies and booting them from the iconic index.